4 citations
,
November 2023 in “Frontiers in immunology” New treatments targeting T-cell pathways are needed for better alopecia areata management.
238 citations
,
November 2016 in “Journal of The American Academy of Dermatology” Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.
May 2025 in “Orphanet Journal of Rare Diseases” TNF-α blockers and IL inhibitors improve symptoms in most patients with severe scalp condition, but more research is needed.
January 2013 in “Yearbook of Urology” The Princeton III Consensus recommends assessing cardiovascular risk in men with erectile dysfunction and prioritizing heart health before treating ED, especially in those with potential heart disease.
2 citations
,
October 2018 in “Springer eBooks” Cancer treatments can cause skin-related side effects that may affect patient quality of life and require changes in treatment.
June 2017 in “Journal of the American Academy of Dermatology” Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.
September 2014 in “Aktuelle Dermatologie” The symposium concluded that environmental factors significantly contribute to skin aging.
98 citations
,
January 2013 in “Journal of The American Academy of Dermatology” Dutasteride may help stabilize Frontal Fibrosing Alopecia, but more research is needed.
63 citations
,
July 2024 in “Journal of the American Academy of Dermatology” Deuruxolitinib effectively promotes hair regrowth in adults with alopecia areata.
3 citations
,
November 2024 in “Pediatric Dermatology” Selumetinib causes fewer and less severe skin issues in children than binimetinib.
1 citations
,
February 2018 in “The Journal of Sexual Medicine” Ultrasound shows 96% of young men with erectile dysfunction after using finasteride have abnormal penile tissue.
1 citations
,
July 2014 in “Our Dermatology Online” The patient with both scarring and non-scarring hair loss showed complex immune reactions and improved with steroid treatment.
JAK inhibitors effectively regrow hair in children with alopecia areata and are safe to use.
May 2024 in “European urology focus” Drugs for prostate enlargement and hair loss were not linked to increased risk of depression or suicide.
April 2024 in “Archives of toxicology” Certain substances can protect against ear damage from some antibiotics in zebrafish.
February 2013 in “Journal of The American Academy of Dermatology” Hair loss is a common, often overlooked side effect of hormone treatments for breast and prostate cancer.
February 2013 in “Journal of The American Academy of Dermatology” Hair loss is a common side effect of hormone treatments for cancer.
35 citations
,
May 2012 in “Expert Opinion on Pharmacotherapy” The document concludes that there are various treatments for different types of alopecia, but more research is needed for evidence-based treatments.
17 citations
,
June 2020 in “British Journal of Dermatology” Oral mTOR inhibitors often cause skin and hair side effects but usually don't require stopping treatment.
13 citations
,
December 2024 in “Cellular and Molecular Life Sciences” Caspases do more than kill cells; they also help in cell growth and disease, and targeting them could lead to new treatments.
2 citations
,
February 2025 in “Archives of Dermatological Research” Baricitinib is a safe and effective alternative for alopecia areata patients who do not respond to tofacitinib.
2 citations
,
September 2023 in “Journal of the American Academy of Dermatology” CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.
1 citations
,
March 2019 in “Actas Dermo-Sifiliográficas” New cancer treatments are less harmful to hair but can still cause hair loss, color, shape, and growth changes.
1 citations
,
March 2011 in “Journal of Investigative Dermatology” Blocking RANK signaling might help treat metastatic melanoma, but more research is needed.
January 2005 in “Urologia Journal” 5αR inhibitors help slow early prostate cancer cell growth, suggesting combined treatments are needed.
56 citations
,
July 2008 in “European journal of endocrinology” Metformin and rosiglitazone improve blood vessel function in women with PCOS, with metformin also reducing insulin resistance and testosterone levels.
451 citations
,
March 2005 in “Endocrine Reviews” The enzyme steroid sulfatase is linked to breast cancer and other conditions, and inhibitors are being developed for treatment.
355 citations
,
January 2017 in “Journal of the American Academy of Dermatology” JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.
153 citations
,
November 2004 in “Current Medicinal Chemistry” The document concludes that Catalyst software is effective for drug design, identifying potent compounds for various medical conditions.
130 citations
,
February 2018 in “Journal of Investigative Dermatology” Tofacitinib may help treat severe hair loss, but more research is needed.